Department of Anaesthesia and Pain Medicine, Royal Perth Hospital, Perth, Australia.
Ann Acad Med Singap. 2009 Nov;38(11):960-6.
The use of opioids for the treatment of chronic non-cancer pain has become more widespread recently. Available data support the short-term use of opioids in clearly defined nociceptive and neuropathic pain states. Their use in 'pathological' pain states without a clear diagnosis, such as chronic low back pain, is more contentious. A decision to initiate opioid treatment in these conditions requires careful consideration of benefits and risks; the latter include not only commonly considered adverse effects such as constipation, but also opioid-induced hyperalgesia, abuse, addiction and diversion. Ideally, treatment goals should not only be relief of pain, but also improvement of function. Opioid treatment of chronic non-cancer pain requires informed consent by, and preferably a treatment contract with, the patient. Treatment should be initiated by a trial period with defined endpoints using slow-release or transdermal opioids. Ongoing management of the patient requires ideally a multi-disciplinary setting. Treatment should not be regarded as life-long and can be discontinued by tapering the dose.
最近,阿片类药物在慢性非癌性疼痛治疗中的应用越来越广泛。现有数据支持在明确的伤害感受性和神经性疼痛状态下短期使用阿片类药物。在没有明确诊断的“病理性”疼痛状态下使用阿片类药物,如慢性腰痛,争议更大。在这些情况下开始使用阿片类药物治疗需要仔细考虑利弊;后者不仅包括常见的不良反应,如便秘,还包括阿片类药物引起的痛觉过敏、滥用、成瘾和转移。理想情况下,治疗目标不仅应是缓解疼痛,还应改善功能。慢性非癌性疼痛的阿片类药物治疗需要患者知情同意,最好是与患者签订治疗合同。治疗应通过使用缓释或透皮阿片类药物的规定期限的试验期开始。对患者的持续管理理想情况下需要多学科设置。治疗不应被视为终身治疗,可以通过逐渐减少剂量来停止。